SG11202002366VA - Agonistic cd40 antibodies - Google Patents

Agonistic cd40 antibodies

Info

Publication number
SG11202002366VA
SG11202002366VA SG11202002366VA SG11202002366VA SG11202002366VA SG 11202002366V A SG11202002366V A SG 11202002366VA SG 11202002366V A SG11202002366V A SG 11202002366VA SG 11202002366V A SG11202002366V A SG 11202002366VA SG 11202002366V A SG11202002366V A SG 11202002366VA
Authority
SG
Singapore
Prior art keywords
agonistic
antibodies
Prior art date
Application number
SG11202002366VA
Other languages
English (en)
Inventor
Stephan Fischer
Karsten Beckmann
Original Assignee
Mab Discovery Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mab Discovery Gmbh filed Critical Mab Discovery Gmbh
Publication of SG11202002366VA publication Critical patent/SG11202002366VA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732Antibody-dependent cellular cytotoxicity [ADCC]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75Agonist effect on antigen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11202002366VA 2017-09-19 2018-09-19 Agonistic cd40 antibodies SG11202002366VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17191974 2017-09-19
PCT/EP2018/075388 WO2019057792A1 (fr) 2017-09-19 2018-09-19 Anticorps cd40 agonistes

Publications (1)

Publication Number Publication Date
SG11202002366VA true SG11202002366VA (en) 2020-04-29

Family

ID=59914405

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202002366VA SG11202002366VA (en) 2017-09-19 2018-09-19 Agonistic cd40 antibodies

Country Status (14)

Country Link
US (2) US11702478B2 (fr)
EP (1) EP3684813A1 (fr)
JP (2) JP7346390B2 (fr)
KR (1) KR20200063139A (fr)
CN (2) CN111225924B (fr)
AU (1) AU2018335828A1 (fr)
BR (1) BR112020003988A2 (fr)
CA (1) CA3075221A1 (fr)
EA (1) EA202090791A1 (fr)
IL (1) IL272770A (fr)
MX (1) MX2020002984A (fr)
SG (1) SG11202002366VA (fr)
WO (1) WO2019057792A1 (fr)
ZA (1) ZA202001066B (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116057070A (zh) * 2019-10-23 2023-05-02 礼进生物医药科技(上海)有限公司 抗cd40结合分子和包括其的双特异性抗体
KR20230020521A (ko) * 2020-06-04 2023-02-10 셀벡스 피티와이 리미티드 아고니스트 항-cd40 항체
CN113861292A (zh) * 2020-06-30 2021-12-31 百奥泰生物制药股份有限公司 抗cd40抗体或抗原结合片段及其应用
WO2023052581A1 (fr) * 2021-10-01 2023-04-06 Mab Discovery Gmbh Anticorps anti-cd40 agonistes en tant qu'agents immunostimulateurs
WO2024005423A1 (fr) * 2022-06-29 2024-01-04 고려대학교 산학협력단 Variants fc glycosylés ayant une affinité de liaison pour fcγrs humains supprimée

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2009027B1 (fr) * 2001-04-27 2014-05-21 Kyowa Hakko Kirin Co., Ltd. Anticorps monoclonal anti-CD40
AR039067A1 (es) * 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US7563443B2 (en) * 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
TWI461211B (zh) 2009-03-20 2014-11-21 Genentech Inc 抗-her抗體
AR083847A1 (es) 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
CN113461819B (zh) 2011-04-29 2024-01-02 埃派斯进有限公司 抗-cd40抗体及其使用方法
GB201115280D0 (en) 2011-09-05 2011-10-19 Alligator Bioscience Ab Antibodies, uses and methods
CA2943167A1 (fr) 2014-03-24 2015-10-01 University Of Southampton Anticorps modifies contenant des domaines d'igg2 modifies conferant des proprietes agonistes ou antagonistes, et utilisation de ces derniers
JP2018526977A (ja) 2015-06-29 2018-09-20 ザ ロックフェラー ユニヴァーシティ アゴニスト活性が増強されたcd40に対する抗体
GB201601073D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies
ES2906823T3 (es) 2015-09-30 2022-04-20 Janssen Biotech Inc Anticuerpos agonistas que se unen específicamente a CD40 humano y métodos de uso
EA201892362A1 (ru) 2016-04-18 2019-04-30 Селлдекс Терапьютикс, Инк. Агонистические антитела, которые связываются с cd40 человека, и варианты их применения
BR112019000512A2 (pt) * 2016-07-14 2019-04-24 Genmab A/S anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, composição, métodos de tratamento de uma doença, para produzir um anticorpo biespecífico e para detectar se a reticulação entre as células que expressam cd40 e cd137 ocorre em uma amostra, uso de um anticorpo multiespecífico, e, kit
EP3401332A1 (fr) 2017-05-08 2018-11-14 MAB Discovery GmbH Anticorps anti-il-1r3 destinés à être utilisés dans des conditions inflammatoires

Also Published As

Publication number Publication date
CA3075221A1 (fr) 2019-03-28
JP7346390B2 (ja) 2023-09-19
AU2018335828A1 (en) 2020-03-05
EA202090791A1 (ru) 2020-06-17
CN111225924B (zh) 2023-10-10
EP3684813A1 (fr) 2020-07-29
ZA202001066B (en) 2021-09-29
JP2023182583A (ja) 2023-12-26
WO2019057792A1 (fr) 2019-03-28
JP2020534292A (ja) 2020-11-26
US11702478B2 (en) 2023-07-18
KR20200063139A (ko) 2020-06-04
US20200239583A1 (en) 2020-07-30
BR112020003988A2 (pt) 2020-09-01
MX2020002984A (es) 2020-07-22
CN117551197A (zh) 2024-02-13
IL272770A (en) 2020-04-30
CN111225924A (zh) 2020-06-02
US20240010741A1 (en) 2024-01-11

Similar Documents

Publication Publication Date Title
IL268517A (en) Anti-tigit antibodies
ZA201905966B (en) Anti-lag3 antibodies
IL272227A (en) ANTI-TIGIT antibodies
HK1245807A1 (zh) 抗mertk的激活型抗體及其應用
HK1251974A1 (zh) 人源化抗cd40抗體及其用途
GB201709808D0 (en) Antibodies
IL273393A (en) New epsilon anti-CD3 antibodies
SG10201914130VA (en) GARP-TGF-β ANTIBODIES
ZA202002141B (en) Anti-transthyretin antibodies
ZA202001066B (en) Agonistic cd40 antibodies
GB201720970D0 (en) Antibodies
ZA202103456B (en) Anti-alpha-synuclein antibodies
IL271067A (en) Anti-trkb antibodies
PT3601700T (pt) Membro divisor para boiserie
GB201711785D0 (en) Antibodies
GB201717006D0 (en) Anti-OPG antibodies
GB201709818D0 (en) Antibodies
GB201703071D0 (en) Antibodies
GB201701416D0 (en) Anti-OPG antibodies